The Claim
In Japanese adults with type 2 diabetes, two weeks of treatment with linagliptin or liraglutide does not impair the glucagon response to induced hypoglycemia at 2.5 mmol/L, as measured by plasma glucagon levels during a hypoglycemic clamp test.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In Japanese adults with type 2 diabetes, two weeks of treatment with linagliptin or liraglutide does not reduce the increase in plasma glucagon levels when blood sugar is lowered to 2.5 mmol/L during a controlled test.
See the scientific wording
In Japanese adults with type 2 diabetes, two weeks of treatment with the DPP-4 inhibitor linagliptin or the GLP-1 receptor agonist liraglutide does not impair the glucagon response to induced hypoglycemia at 2.5 mmol/L, as measured by plasma glucagon levels during a hypoglycemic clamp test, suggesting both drugs preserve this critical counter-regulatory defense against low blood sugar.
When blood sugar drops, pancreatic alpha cells release glucagon to raise it back up; this response stays strong even when drugs block the breakdown of GLP-1 or activate its receptor, because the alpha cells still sense low glucose and respond directly without being suppressed.
What the research says
1 studyThe study found that two weeks of taking either linagliptin or liraglutide didn’t stop the body from releasing glucagon when blood sugar drops too low — which is good because glucagon helps raise blood sugar back up and prevents dangerous lows.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.